84 related articles for article (PubMed ID: 28582844)
1. Postoperative recurrence analysis of breast cancer patients based on clinical serum markers using discriminant methods.
Li L; Gao Q; Xu G; Shi B; Ma X; Liu H; Li Q; Tian T; Tang J; Niu H
Cancer Biomark; 2017 Jul; 19(4):403-409. PubMed ID: 28582844
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
4. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
5. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer.
Gaspar MJ; Diez M; Rodriguez A; Ratia T; Martin Duce A; Galvan M; Granell J; Coca C
Anticancer Res; 2003; 23(4):3427-32. PubMed ID: 12926084
[TBL] [Abstract][Full Text] [Related]
7. Different Levels of CEA, CA153 and CA125 in Milk and Benign and Malignant Nipple Discharge.
Zhao S; Mei Y; Wang J; Zhang K; Ma R
PLoS One; 2016; 11(6):e0157639. PubMed ID: 27327081
[TBL] [Abstract][Full Text] [Related]
8. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
9. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
[TBL] [Abstract][Full Text] [Related]
10. Early detection of recurrent breast cancer using metabolite profiling.
Asiago VM; Alvarado LZ; Shanaiah N; Gowda GA; Owusu-Sarfo K; Ballas RA; Raftery D
Cancer Res; 2010 Nov; 70(21):8309-18. PubMed ID: 20959483
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of Serum Carcinoembryonic Antigen Levels after Curative Resection of Colon Cancer: Cutoff Values Determined according to Preoperative Levels Enhance the Diagnostic Accuracy for Recurrence.
Saito G; Sadahiro S; Kamata H; Miyakita H; Okada K; Tanaka A; Suzuki T
Oncology; 2017; 92(5):276-282. PubMed ID: 28178692
[TBL] [Abstract][Full Text] [Related]
13. Plasma fibrinogen level may be a possible marker for the clinical response and prognosis of patients with breast cancer receiving neoadjuvant chemotherapy.
Mei Y; Liu H; Sun X; Li X; Zhao S; Ma R
Tumour Biol; 2017 Jun; 39(6):1010428317700002. PubMed ID: 28621233
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic potential of serum angiopoietin-2 expression in human breast cancer.
Li P; He Q; Luo C; Qian L
Int J Clin Exp Pathol; 2015; 8(1):660-4. PubMed ID: 25755760
[TBL] [Abstract][Full Text] [Related]
15. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.
Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T
Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
17. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
El-Attar NI; Gaefar HA
Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Serum Fructosamine as Diagnostic Marker of Postoperative Recurrence in the Patients with Breast Cancer.
Zhao Y; Xie X; Xie J; Zhang L; Li B; Liu J; Jiang H
Biomed Res Int; 2023; 2023():6435776. PubMed ID: 37475819
[TBL] [Abstract][Full Text] [Related]
19. Elevated level of serum glycoprotein bifucosylation and prognostic value in Chinese breast cancer.
Ju L; Wang Y; Xie Q; Xu X; Li Y; Chen Z; Li Y
Glycobiology; 2016 May; 26(5):460-71. PubMed ID: 26646445
[TBL] [Abstract][Full Text] [Related]
20. Serum carbohydrate antigen 125 is a significant prognostic marker in patients with unresectable advanced or recurrent gastric cancer.
Namikawa T; Kawanishi Y; Fujisawa K; Munekage E; Iwabu J; Munekage M; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Surg Today; 2018 Apr; 48(4):388-394. PubMed ID: 29043453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
